In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.
   PubMed Web of Science ®Google Scholar
• Joshi P, Dutta S, Chaturvedi P, Nair S. Head and neck cancers in developing countries. Rambam Maimonides Med J. 2014;5:e0009. doi:10.5041/RMMJ.20769172.
   PubMedGoogle Scholar
• Gilyoma JM, Rambau PF, Masalu N, Kayange NM, Chalya PL. Head and neck cancers: a clinico-pathological profile and management challenges in a resource-limited setting. BMC Res Notes. 2015;8:772. doi:10.1186/s13104-015-1773-9.
   PubMedGoogle Scholar
• Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, Stoker S, Kurnianda J, Karakullukcu B, Taroeno-Hariadi KW, et al. Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. PloS one. 2013;8:e63706. doi:10.1371/journal.pone.0063706.
   PubMed Web of Science ®Google Scholar
• Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994–1001. doi:10.1634/theoncologist.2009-0289.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–61. doi:10.1093/annonc/mdq453.
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–965. doi:10.1016/S1470-2045(16)30066-3.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. The New England journal of medicine. 2016. doi:10.1056/NEJMoa1602252
   Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242. doi:10.1038/nri3405.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 2011;17:343–350. doi:10.1097/PPO.0b013e318233e5b2.
   PubMed Web of Science ®Google Scholar
• Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015;21:312–321. doi:10.1158/1078-0432.CCR-14-0202.
   PubMed Web of Science ®Google Scholar
• Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Phase I trial of Wilms’ Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 2012;32:2263–2269.
   PubMed Web of Science ®Google Scholar
• Chong CE, Lim KP, Gan CP, Marsh CA, Zain RB, Abraham MT, Prime SS, Teo S-H, Silvio Gutkind J, Patel V, et al. Over-expression of MAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome. Cancer Lett. 2012;321:18–26. doi:10.1016/j.canlet.2012.03.025.
   PubMed Web of Science ®Google Scholar
• Ahmad Zabidi MM Identification of four-jointed box 1 as a potential oncogene in nasopharyngeal carcinoma. M.Sc. Thesis. Institute of Biological Sciences, Faculty of Science. Kuala Lumpur. (http://pendeta.um.edu.my/client/default/search/detailnonmodal/ent:$002f$002fSD_ILS$002f871$002fSD_ILS:871872/one;jsessionid=55866C8DEF2376DCA6A645D4DCFFDBE1.enterprise-20200?qu=%22871872%22&te=ILS): University of Malaya,2011:100.
   Google Scholar
• Chai SJ, Yap YY, Foo YC, Yap LF, Ponniah S, Teo SH, Cheong SC, Patel V, Lim KP, Zhang L. Identification of Four-Jointed Box 1 (FJX1)-specific peptides for immunotherapy of Nasopharyngeal Carcinoma. PloS one. 2015;10:e0130464. doi:10.1371/journal.pone.0130464.
   PubMed Web of Science ®Google Scholar
• Lim KP, Chun NA, Gan CP, Teo SH, Rahman ZA, Abraham MT, Zain RB, Ponniah S, Cheong SC. Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy. Hum Vaccin Immunother. 2014;10:3214–3223. doi:10.4161/hv.29226.
   PubMed Web of Science ®Google Scholar
• Cheong SC, Chandramouli GV, Saleh A, Zain RB, Lau SH, Sivakumaren S, Pathmanathan R, Prime SS, Teo SH, Patel V, et al. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. Oral Oncol. 2009;45:712–719. doi:10.1016/j.oraloncology.2008.11.002.
   PubMed Web of Science ®Google Scholar
• Bose S, Yap LF, Fung M, Starzcynski J, Saleh A, Morgan S, Dawson C, Chukwuma MB, Maina E, Buettner M, et al. The ATM tumour suppressor gene is down-regulated in EBV-associated nasopharyngeal carcinoma. J Pathol. 2009;217:345–352. doi:10.1002/path.2487.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576–582. doi:10.1038/nature14129.
   PubMed Web of Science ®Google Scholar
• Rock R, Heinrich AC, Schumacher N, Gessler M. Fjx1: a notch-inducible secreted ligand with specific binding sites in developing mouse embryos and adult brain. Dev Dyn. 2005;234:602–612. doi:10.1002/dvdy.20553.
   PubMed Web of Science ®Google Scholar
• Al-Greene NT, Means AL, Lu P, Jiang A, Schmidt CR, Chakravarthy AB, Merchant NB, Washington MK, Zhang B, Shyr Y, et al. Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. PloS one. 2013;8:e69660. doi:10.1371/journal.pone.0069660.
   PubMed Web of Science ®Google Scholar
• Inaoka RJ, Jungbluth AA, Baiocchi OC, Assis MC, Hanson NC, Frosina D, Tassello J, Bortoluzzo AB, Alves AC, Colleoni GW. An overview of cancer/testis antigens expression in classical Hodgkin’s lymphoma (cHL) identifies MAGE-A family and MAGE-C1 as the most frequently expressed antigens in a set of Brazilian cHL patients. BMC Cancer. 2011;11:416. doi:10.1186/1471-2407-11-416.
   PubMed Web of Science ®Google Scholar
• Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget. 2015;6:15772–15787. doi:10.18632/oncotarget.4694.
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens CR, Lai j, Postovit L-M, et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate. 2011;71:1198–1209. doi:10.1002/pros.21335.
   PubMed Web of Science ®Google Scholar
• Becker D, Sfakianakis I, Krupp M, Staib F, Gerhold-Ay A, Victor A, Binder H, Blettner M, Maass T, Thorgeirsson S, et al. Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. Mol Cancer. 2012;11:55. doi:10.1186/1476-4598-11-55.
   PubMed Web of Science ®Google Scholar
• Slingluff CL, Jr., Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48:661–672. doi:10.1007/s002620050015.
   PubMed Web of Science ®Google Scholar
• Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, Gottschalk SM, Savoldo B, Vera JF, Heslop HE, et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Therapy. 2011;19:2258–2268. doi:10.1038/mt.2011.167.
   PubMed Web of Science ®Google Scholar
• Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Badet L, Hauet T. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med. 2012;10:141. doi:10.1186/1479-5876-10-233.
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver K, Sayers T, Strobl S, Derby E, Ulderich T, Baseler M, Malyguine A. The Granzyme B ELISPOT assay: an alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003;1:14. doi:10.1186/1479-5876-1-14.
   PubMedGoogle Scholar
• Huijbers EJM, van Beijnum JR, Le CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW. An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. Vaccine. 2018. doi: 10.1016/j.vaccine.2018.03.064.
   PubMed Web of Science ®Google Scholar
• Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E. Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol. 2012;2012:926321. doi:10.1155/2012/926321.
   PubMed Web of Science ®Google Scholar
• Ahrends T, Babala N, Xiao Y, Yagita H, van Eenennaam H, Borst J. CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination. Cancer Res. 2016;76:2921–2931. doi:10.1158/0008-5472.CAN-15-3130.
   PubMed Web of Science ®Google Scholar
• Morse MA, Lyerly HK. Checkpoint blockade in combination with cancer vaccines. Vaccine. 2015;33:7377–7385. doi:10.1016/j.vaccine.2015.10.057.
   PubMed Web of Science ®Google Scholar
• Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem-Yehudar R, Cook L, Khleif SN. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol. 2011;41:2977–2986. doi:10.1002/eji.201141639.
   PubMed Web of Science ®Google Scholar
• Avogadri F, Zappasodi R, Yang A, Budhu S, Malandro N, Hirschhorn-Cymerman D, Tiwari S, Maughan MF, Olmsted R, Wolchok JD, et al. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res. 2014;2:448–458. doi:10.1158/2326-6066.CIR-13-0220.
   PubMed Web of Science ®Google Scholar
• Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, Behrens MD, Knutson KL. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res. 2014;74:2974–2985. doi:10.1158/0008-5472.CAN-13-2564.
   PubMed Web of Science ®Google Scholar
• Sharma S, Dominguez AL, Lustgarten J. Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol. 2006;41:78–84. doi:10.1016/j.exger.2005.10.002.
   PubMed Web of Science ®Google Scholar
• Gruver AL, Hudson LL, Sempowski GD. Immunosenescence of ageing. J Pathol. 2007;211:144–156. doi:10.1002/path.2104.
   PubMed Web of Science ®Google Scholar
• Wu C, Jin X, Tsueng G, Afrasiabi C, Su AI. BioGPS: building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res. 2016;44:D313–6. doi:10.1093/nar/gkv1104.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28:1248–1250. doi:10.1038/nbt1210-1248.
   PubMed Web of Science ®Google Scholar
• Lyon JG, Mokarram N, Saxena T, Carroll SL, Bellamkonda RV. Engineering challenges for brain tumor immunotherapy. Adv Drug Deliv Rev. 2017;114:19–32. doi:10.1016/j.addr.2017.06.006.
   PubMed Web of Science ®Google Scholar
• Gan CP, Patel V, Mikelis CM, Zain RB, Molinolo AA, Abraham MT, Teo S-H, Abdul Rahman ZA, Gutkind JS, Cheong SC. Heterotrimeric G-protein alpha-12 (Galpha12) subunit promotes oral cancer metastasis. Oncotarget. 2014;5:9626–9640. doi:10.18632/oncotarget.2437.
   PubMedGoogle Scholar
• Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol. 2004;202:265–273. doi:10.1002/path.1515.
   PubMed Web of Science ®Google Scholar